Preparation method and application of a chanocloum compound

CN122521463APending Publication Date: 2026-08-07SOUTHERN MEDICAL UNIVERSITY +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610765653.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-05-29
Publication Date
2026-08-07

AI Technical Summary

Technical Problem

天然或野生的真菌菌株来源的拟盘菲酮A(PPA)产量较低,满足不了新药研发的需求

Benefits of technology

1. 本发明提供了利用异源表达工程菌株制备PPA的方法,该方法避免了从天然或野生真菌菌株中分离PPA面临的发酵周期长、产量低、同系物多、分离难度大的问题,为新药研发提供了理想的药源保障。具体而言,Aspergillus nidulansSE44的发酵周期为3天,产量为1.04 mg/L,且几乎不产生同系物,分离纯化难度极低。相比之下,野生型菌株的发酵周期长达30天,在液体培养基中几乎不产生PPA,需采用大米固体培养基才能获得目标产物(产量约为3.5 mg/kg),同时伴有多达38种同系物,分离难度极大。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122521463A_ABST
    Figure CN122521463A_ABST
Patent Text Reader

Abstract

The application discloses a preparation method and application of a discodermolide compound. Aspergillus nidulans The discodermolide compound is obtained from a strain of Aspergillus nidulans SE44 Aspergillus nidulans The strain of Aspergillus nidulans SE44 is preserved in the Guangdong Microbial Culture Collection Center on April 15, 2026, and has a preservation number of GDMCC No:68088. It is found that discodermolide A can target the activation of LXR alpha by covalently combining with the R305 site of the LXR alpha protein, thereby regulating the LXR alpha-SLC31A1 signal pathway, inhibiting the generation of ROS, reducing the damage of oxidative stress to kidney tissue, and achieving the treatment effect on acute kidney injury.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, and in particular relates to a method for preparing and applying a pseudophenanthrene compound. Background Technology

[0002] Acute kidney injury (AKI) is a common and critical clinical condition characterized by rapid decline in renal function, damage to renal tubular epithelial cells, and disruption of the renal inflammatory microenvironment. It often occurs secondary to ischemia-reperfusion injury, exposure to nephrotoxic drugs, and infection, and has an extremely high incidence in cases of kidney transplantation, cardiac surgery, and severe sepsis. Currently, there are no specific anti-AKI drugs, and clinical treatment primarily relies on supportive measures such as fluid resuscitation and renal replacement therapy. Patients not only face the risk of poor renal function recovery but are also prone to progressing to chronic kidney disease and even end-stage renal disease, placing a heavy burden on global healthcare systems.

[0003] Oxidative stress is a key pathological factor mediating the development of acute kidney injury (ARDS). When the kidneys are exposed to external stimuli such as ischemia and toxic substances, a large amount of reactive oxygen species (ROS) are generated in the body. When the amount of ROS exceeds the body's own antioxidant capacity, it directly damages renal tubular epithelial cells, disrupts mitochondrial homeostasis, and induces apoptosis. At the same time, excessive accumulation of ROS further activates the body's inflammatory response, ultimately accelerating the rapid deterioration of kidney function. This provides an important pathological intervention direction for the treatment of ARDS.

[0004] Liver X receptor α (LXRα), an important member of the nuclear receptor superfamily, is a key transcription factor regulating lipid metabolism, inflammatory responses, apoptosis, and mitochondrial function, and it is highly expressed in kidney tissue. Previous studies have shown that LXRα can participate in and improve the pathological process of acute kidney injury by maintaining mitochondrial homeostasis and inhibiting excessive accumulation of reactive oxygen species. Therefore, novel LXRα modulators hold promise as potential target molecules for the treatment of acute kidney injury.

[0005] Papaverne A (PPA) is a novel azophenone compound derived from fungi with promising biological activity potential. However, the yield of PPA from natural or wild-type fungal strains is low, insufficient to meet the needs of new drug development. Furthermore, there are currently no reports on the binding activity of PPA to the LXRα target, its application value in the treatment of acute kidney injury, or its specific molecular mechanism. Summary of the Invention

[0006] To address the aforementioned technical problems, this invention provides a method for preparing and applying psyllphenanthrone compounds. This invention constructs a heterologous expression engineered strain that can stably and continuously produce psyllphenanthrone A (PAA). Experiments have demonstrated that PPA can act as an LXRα agonist regulating oxidative stress, and holds promise for the treatment of liver and kidney diseases caused by lipid metabolism and oxidative stress disorders.

[0007] To achieve the above objectives, the technical solution adopted by the present invention is as follows: On the one hand, the present invention provides a strain of Aspergillus nidulans, which is named Aspergillus nidulans SE44, taxonomically named Aspergillus nidulans It was deposited at the Guangdong Provincial Center for Microbial Culture Collection on April 15, 2026, with accession number GDMCC No: 68088.

[0008] In another aspect, the present invention provides a method for constructing the above-mentioned Aspergillus nidulans strain, comprising: pes L gene ,pes E gene ,pes F gene ,pes I gene and pes J gene introduced into chassis cells Aspergillus nidulans The steps in A1145.

[0009] In the technical solution of the present invention, the pes L gene ,pes E gene ,pes F gene ,pes I gene and pes The J gene originates from the strain. Neopestalotiopsis sp. SCSIO41422, its taxonomic name is Neopestalotiopsis sp. was deposited at the Guangdong Provincial Center for Microbial Culture Collection on August 4, 2022, with accession number GDMCC No: 62689. pes The nucleotide sequence of the L gene is shown in SEQ ID NO.1; pes The nucleotide sequence of the E gene is shown in SEQ ID NO.2; pes The nucleotide sequence of the F gene is shown in SEQ ID NO.3; pes The nucleotide sequence of gene I is shown in SEQ ID NO.4; pes The nucleotide sequence of the J gene is shown in SEQ ID NO.5.

[0010] In a preferred embodiment, the construction method includes the following steps: (1) Using strains Neopestalotiopsis Using the genomic DNA of sp. SCSIO41422 as a template, PCR amplification was performed to obtain... pes L gene ,pes E gene ,pes F gene ,pes I gene and pes J gene; (2) The gene fragment obtained in step (1) and the linearized vector were co-transformed into competent yeast cells to obtain yeast plasmids; (3) The yeast was transformed into competent E. coli cells, and the presence of the yeast was verified. pes Recombinant plasmids containing the L gene pes E gene and pes Recombinant plasmids containing the F gene pes I gene and pes Recombinant plasmid of the J gene; (4) Transform the recombinant plasmid obtained in step (3) into Aspergillus nidulans and screen for plasmids containing Aspergillus nidulans. pes L gene ,pes E gene ,pes F gene ,pes I gene and pes Aspergillus nidulans of the J gene was used to obtain strains. Aspergillus nidulans SE44.

[0011] In a preferred embodiment, in step (2), the linearized vector is a vector obtained by double digestion of pYTU plasmid, pYTR plasmid, and pYTP plasmid with restriction endonucleases PacI and SwaI. Preferably, in step (3), the competent Escherichia coli cells are Escherichia coli DH5α competent cells.

[0012] In another aspect, the present invention provides a method for preparing a pseudophenanthrone compound, wherein the pseudophenanthrone compound is pseudophenanthrone A, and its structure is shown in formula (1); the pseudophenanthrone compound is prepared by Aspergillus nidulans strain Aspergillus nidulans It was isolated from the fermentation products of SE44.

[0013] Equation (1).

[0014] In a preferred embodiment, the preparation method of the pseudophenanthrone A includes the following steps: (1) For the aforementioned Aspergillus nidus strain Aspergillus nidulans SE44 was subjected to fermentation treatment; (2) The fermentation product was extracted with ethyl acetate and concentrated to obtain a crude extract; (3) The pseudophenanthrene compounds were obtained by gradient elution and purification by reverse silica gel column chromatography.

[0015] In a preferred embodiment, in step (1), the fermentation treatment is as follows: the Aspergillus nidulans strain... Aspergillus nidulans SE44 was inoculated into liquid CD-ST medium and allowed to ferment statically; Preferably, each liter of the liquid CD-ST culture medium contains: 20 g of soluble starch, 20 g of vitamin-free casein hydrolysate, 50 mL of nitrate solution, 1 mL of trace element solution, and the remainder is water; the nitrate solution contains: 120 g / L sodium nitrate, 10.4 g / L potassium chloride, 10.4 g / L magnesium sulfate, and 30.4 g / L potassium dihydrogen phosphate; the trace element solution contains: 22 g / L zinc sulfate heptahydrate, 11 g / L boric acid, 5 g / L manganese chloride tetrahydrate, 1.6 g / L ferrous sulfate heptahydrate, 1.6 g / L cobalt chloride hexahydrate, 1.6 g / L copper sulfate pentahydrate, 1.1 g / L ammonium heptamolybdate tetrahydrate, and 50 g / L EDTA; the pH of the trace element solution is adjusted to 6.5 with KOH.

[0016] In a preferred embodiment, in step (3), the reverse silica gel column chromatography gradient elution yields fractions 1-14; the eluent for the reverse silica gel column chromatography gradient elution is methanol-water; the gradient for the reverse silica gel column chromatography gradient elution is methanol / water = 10% / 90% → 16.5% / 83.5% → 23% / 77% → 29.5% / 70.5% → 36% / 64% → 42.5% / 57.5% → 49% / 51% → 55.5% / 44.5% → 62% / 38% → 68.5% / 31.5% → 75% / 25% → 81.5% / 18.5% → 88% / 12% → 94.5% / 5.5% → 100% / 0. Preferably, fraction 10 obtained by reverse silica gel column chromatography gradient elution is purified to obtain pseudophenanthrene compounds; the purification is a semi-preparative HPLC purification; the mobile phase of the semi-preparative HPLC purification is 70% CH3OH / H2O, the flow rate is 3 mL / min, and the retention time is t. R =15.2 min.

[0017] In another aspect, the present invention provides the application of phenanthrene compounds in the preparation of LXRα agonists, wherein the phenanthrene compound is phenanthrene A, and the structure is shown in formula (1).

[0018] Equation (1).

[0019] In another aspect, the present invention provides the use of phenanthrene compounds and their pharmaceutical salts in the preparation of medicaments for the treatment and / or prevention of liver and kidney diseases, wherein the phenanthrene compound is phenanthrene A, and the structure is shown in formula (1).

[0020] Equation (1) Preferably, the liver and kidney disease is a liver and kidney disease caused by lipid metabolism and oxidative stress disorders.

[0021] Preferably, the liver and kidney diseases include non-alcoholic fatty liver disease, diabetic nephropathy, and acute kidney injury.

[0022] This invention is the first to discover that PPA can covalently bind to the R305 site of LXRα, target and activate LXRα, and regulate oxidative stress by modulating the LXRα-SLC31A1 signaling pathway, thereby playing a therapeutic and / or preventive role in liver and kidney diseases caused by lipid metabolism and oxidative stress disorders.

[0023] Compared with the prior art, the present invention has the following significant advantages: 1. This invention provides a method for preparing PPA using heterologous expression engineered strains. This method avoids the problems of long fermentation cycles, low yields, numerous homologues, and high isolation difficulty encountered when isolating PPA from natural or wild-type fungal strains, thus providing an ideal source of drug for new drug development. Specifically, Aspergillus nidulans SE44 has a fermentation cycle of 3 days, a yield of 1.04 mg / L, and produces almost no homologues, making isolation and purification extremely easy. In contrast, the wild-type strain has a fermentation cycle of up to 30 days, produces almost no PPA in liquid medium, requires rice solid medium to obtain the target product (yield of approximately 3.5 mg / kg), and produces as many as 38 homologues, making isolation extremely difficult.

[0024] 2. This invention constructs an animal model of unilateral ischemia-reperfusion (UIRIx) acute kidney injury. Through serum creatinine, blood urea nitrogen levels and HE staining results of kidney tissue, it is the first time that PPA can effectively treat acute kidney injury and improve kidney function and histopathological damage.

[0025] 3. This invention is the first to demonstrate that PPA has a covalently targeted activation effect on LXRα, and constructs a PPA probe PPA-P to analyze the binding site, filling the gap in the application of psphenanthrene compounds in the treatment of kidney diseases and overcoming the limitations of existing LXRα agonists.

[0026] 4. This invention elucidates for the first time a novel mechanism by which PPA treats acute kidney injury by regulating the LXRα-SLC31A1 signaling pathway, laying a theoretical foundation for the development of original innovative drugs against acute kidney injury. Attached Figure Description

[0027] Figure 1 The image shows the HPLC analysis chromatogram of the fermentation extract in Example 1 of this invention (the peak with a retention time of 14 min is compound PPA). Figure 2This describes the biosynthetic pathway of PPA in Example 1 of the present invention.

[0028] Figure 3 The results of HE staining in the kidney tissue of UIRIx mice treated with PPA in Example 2 of this invention.

[0029] Figure 4 The levels of creatinine and urea nitrogen in the serum of UIRIx mice treated with PPA in Example 2 of this invention are shown.

[0030] Figure 5 The figure shows the experimental results of PPA targeting LXRα in Example 3 of the present invention.

[0031] Figure 6 The figure shows the experimental results of the covalent binding of PPA and LXRα-R305A in Example 3 of the present invention.

[0032] Figure 7 In Example 4 of this invention, PPA is used to regulate the LXRα-SLC31A1 signaling pathway to treat acute kidney injury.

[0033] Figure 8 The results of ROS detection of PPA in H / R-induced HK-2 cells in Example 4 of this invention are shown.

[0034] Preservation Instructions Aspergillus nidus in this invention Aspergillus nidulans SE44, taxonomically named Aspergillus nidulans It was deposited on April 15, 2026 at the Guangdong Provincial Center for Microbial Culture Collection, with accession number GDMCC No:68088, located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.

[0035] In this invention Neopestalotiopsis sp. SCSIO41422, its taxonomic name is Neopestalotiopsis sp. was deposited on August 4, 2022 at the Guangdong Provincial Center for Microbial Culture Collection, with accession number GDMCC No: 62689, located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou. Detailed Implementation

[0036] The following embodiments are merely some, not all, of the embodiments of the present invention. Therefore, the detailed descriptions of the embodiments provided below are not intended to limit the scope of the claimed invention, but merely to illustrate selected embodiments. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without inventive effort are within the scope of protection of the present invention.

[0037] In this invention, unless otherwise specified, all equipment and raw materials are commercially available or commonly used in the industry. The methods described in the following embodiments are conventional methods in the art, unless otherwise specified.

[0038] Example 1: Construction of Heterologous Expression Engineered Strains and Preparation of PPA (1) PCR amplification of target gene clusters Extraction of strains (marine fungi) capable of producing PPA Neopestalotiopsis Genomic DNA from sp. SCSIO41422 was used as a template. PCR amplification was performed using 2 × Phanta® Max Master Mix high-fidelity enzyme to obtain the target gene. pes L (highly reduced polyketide synthase, nucleotide sequence as shown in SEQ ID NO.1) pes E (non-reducing polyketide synthase, nucleotide sequence as shown in SEQ ID NO.2), pes F (FAD-dependent monooxygenase, nucleotide sequence as shown in SEQ ID NO. 3) pes I (short-chain dehydrogenase, nucleotide sequence as shown in SEQ ID NO.4) and pes J (cytochrome P450 monooxygenase, nucleotide sequence as shown in SEQ ID NO.5), primer sequences are shown in Table 1. PCR reaction system (50 µL): 2 × Phanta® Max Master Mix 25 µL, upstream / downstream primers 2 µL each, DNA template 1 µL, ddH2O 20 µL. Reaction conditions: pre-denaturation 95℃, 3 min; denaturation 95℃, 15 s, annealing 58℃, 15 s, extension 72℃, 1 kb / min, 30 cycles; extension 72℃, 5 min. After the PCR reaction, the amplified product was detected by agarose gel electrophoresis. After verifying the correct band size, the target gene fragment was extracted and purified using a DNA gel extraction kit and stored at -20℃ for later use.

[0039] Table 1

[0040] In this embodiment, pes L, pes The E fragment was too long, resulting in low efficiency of PCR and yeast ligation. Therefore, it was divided into two PCR segments. glaA was used as the promoter, and glaA-F served as the upstream primers for pYTR-glaA-R and pYTP-glaA-R, respectively.

[0041] (2) Construction of heterologous expression plasmids Using brewing yeast Saccharomyces cerevisiaeThe in vivo homologous recombination mechanism of JHY 686 was used to construct heterologous expression plasmids. The specific operation was as follows: the vector plasmids pYTU, pYTR, and pYTP (J. Am. Chem. Soc., 2020, 142, 710–714.) were processed using restriction endonucleases. Pac I and Swa I. Linearization was performed by double enzyme digestion. The target gene fragment amplified by PCR in step (1) was co-transformed with the linearized vector into the host yeast using the Frozen-EZYeast Transformation II Kit (ZYMO RESEARCH). S. cerevisiae JHY 686 competent cells. Specifically, 2 μL of the purified target gene PCR fragment, 1 μL of the corresponding linearized plasmid (pYTU, pYTP, or pYTR), and 300 μL of Frozen-EZ Solution III were added sequentially to a sterile EP tube. After careful mixing, the cells were incubated at 30°C for 1 h, gently mixing every 15 min. The incubated yeast competent cells were then evenly spread on uracil-deficient (Ura-) solid medium plates and cultured at 28°C for 3 days.

[0042] Yeast plasmid extraction and E. coli amplification: 1) Pick an appropriate amount of yeast cells from the Ura-plate and suspend them in a 1.5 mL sterile centrifuge tube containing 150 μL of Digestion Buffer. Add 2.5 μL of Zymolyase™ enzyme solution and mix well. Incubate in a 37°C metal bath for 2 h, inverting the tube several times during this period to promote yeast cell wall rupture. 2) Add 150 μL of Lysis Buffer to the system and invert to mix well; then add 250 μL of Neutralizing Buffer and mix again. Centrifuge at 10,000 rpm for 10 min. 3) Transfer 450 μL of the supernatant to a new 1.5 mL centrifuge tube, add 450 μL of isopropanol and mix well. Centrifuge at 10,000 rpm for 10 min. Discard the supernatant; the precipitate is the DNA plasmid. Add 700 μL of 75% ethanol, mix well, centrifuge at 10000 rpm for 10 min, discard the supernatant, and dry the residual ethanol in a 55℃ metal bath. Add 10 μL of sterile water to dissolve the precipitate to obtain the yeast plasmid sample. 4) Transform the above yeast plasmid into E. coli DH5α competent cells using conventional methods, and plate them on LB solid plates containing carbenicillin resistance (10 g / L peptone, 5 g / L yeast extract, 10 g / L sodium chloride, 20 g / L agar, sterilized) for screening. 5) Pick transformants for colony PCR verification. Inoculate the verified single colonies into 5 mL of LB liquid medium containing carbenicillin resistance and incubate at 37℃ and 200 rpm for 16-18 h with shaking. 6) Extract E. coli plasmids using the Biospin Plasmid DNA Mini Extraction Kit and store at -20℃ for later use. After sequencing verification confirmed that the target gene and vector were correctly ligated, the recombinant plasmid pYTU / was finally obtained. pesL pYTP / pesE / pesF and pYTR / pesI / pesJ .

[0043] (3) Verification of protoplast transformation and fermentation of Aspergillus nidulans The correctly sequenced recombinant plasmid pYTU / pesL pYTP / pesE / pesF and pYTR / pesI / pesJ Transformation to Aspergillus nidulans A. nidulans A1145 ( D Heterologous expression was performed in EM protoplasts. The specific procedure was as follows: Take 4 μL of each of the above recombinant plasmids and mix them with 100 μL of EM protoplasts. mA suspension of *Aspergillus nidulans* protoplasts was mixed and incubated at 4°C or on ice for 60 min to promote plasmid-protoplast binding. Then, 600 μL of PEG 4000 solution was added and gently mixed, and incubated at room temperature for 30 min. The mixture was then evenly spread onto CDS solid medium plates and incubated at 37°C for 3 days. Once single colonies (i.e., containing gene clusters) have grown, [further steps are taken]. pesLEFIJ (Heterologous expression transformants), select single clones and transfer them to CD solid plates, and incubate at 28℃ for 3 days.

[0044] The above-mentioned successfully transformed monoclonal strains A. nidulans A1145 / pes LEFIJ was inoculated into 20 mL of liquid CD-ST medium and allowed to ferment statically for 3 days. After fermentation, mycelia and fermentation broth were collected separately, and an equal volume of ethyl acetate was added for ultrasonic extraction. The extracts were combined, concentrated to dryness under reduced pressure using a rotary evaporator, and then dissolved in a small amount of methanol to obtain the sample to be tested. The sample was analyzed by high-performance liquid chromatography (HPLC) under the following conditions: a Shim-pack GIS C18 column (4.6 × 250 mm, 5 μm); a methanol-water system as the mobile phase, with a flow rate of 1 mL / min; and a gradient elution program of 20 min: 0 min, 20% methanol; 10 min, 100% methanol; 15 min, 100% methanol; 15.1 min, 20% methanol; 20 min, 20% methanol. Based on the HPLC analysis results, an engineered strain that produces PPA efficiently was screened. The HPLC chromatogram is shown below. Figure 1 As shown, the PPA biosynthetic pathway is as follows: Figure 2 As shown.

[0045] The engineered strains that can efficiently produce PPA were screened using the above methods. A. nidulans A1145 / pes LEFIJ named Aspergillus nidulans SE44.

[0046] The reagent and culture medium formulas used in this step are as follows: Ura-deficient (Ura-) solid culture medium: 2.5 g acid-hydrolyzed casein, 10 g glucose, 10 g agar, add 440 mL water, and sterilize. After cooling, add 50 mL Yeast nitrogen base stock solution, 5 mL tryptophan stock solution, and 5 mL adenine stock solution in a clean bench, and store at 4°C.

[0047] Yeast nitrogen base stock solution: 6.7 g of yeast nitrogen source containing ammonium sulfate but no amino acids, diluted to 100 mL with ultrapure water, sterilized by filtration through a 0.22 μm filter membrane, and stored at 4°C. Tryptophan stock solution (2 mg / mL): 40 mg tryptophan, diluted to 20 mL with ultrapure water, sterilized by filtration through a 0.22 μm filter membrane, and stored at 4°C.

[0048] Adenine stock solution (2 mg / mL): 40 mg adenine was suspended in 15 mL of ultrapure water, HCl was added dropwise until completely dissolved, and the volume was adjusted to 20 mL. The solution was then filtered through a 0.22 μm filter membrane for sterilization and stored at 4 °C.

[0049] PEG 4000 solution: 60 g PEG 4000, 50 mM calcium chloride, 50 mM Tris-HCl (pH 7.5), add a small amount of ultrapure water, heat to dissolve, and bring the volume to 100 mL. Sterilize and store at room temperature.

[0050] CDS solid medium: 10 g glucose, 218.6 g sorbitol, 50 mL 20× Nitrate salts, 1 mL Trace Elements, 20 g agar, add water to a final volume of 1 L, sterilize and store at 4°C.

[0051] CD solid plates: 10 g glucose, 50 mL 20× Nitrate salts, 1 mL Trace Elements, 20 g agar, add water to a final volume of 1 L, sterilize and store at 4°C.

[0052] 20× Nitrate salts: 120 g sodium nitrate, 10.4 g potassium chloride, 10.4 g magnesium sulfate, 30.4 g potassium dihydrogen phosphate, add water to a final volume of 1 L, sterilize and store at room temperature.

[0053] Trace Elements: 2.20 g zinc sulfate heptahydrate, 1.10 g boric acid, 0.50 g manganese chloride tetrahydrate, 0.16 g ferrous sulfate heptahydrate, 0.16 g cobalt chloride hexahydrate, 0.16 g copper sulfate pentahydrate, 0.11 g ammonium heptamolybdate tetrahydrate, 5.0 g EDTA. Dissolve in 80 mL of ultrapure water, adjust pH to 6.5 with 1 M KOH, and bring volume to 100 mL.

[0054] CD-ST medium: 20 g soluble starch, 20 g vitamin-free casein hydrolysate, 50 mL 20× Nitrate salts, 1 mL Trace elements, add water to a final volume of 1 L, sterilize and store at room temperature.

[0055] (4) Fermentation of PPA engineered strains and isolation and identification of target compounds The above steps will filter out the selected items. Aspergillus nidulans SE44 was inoculated into 5 L of liquid CD-ST medium and fermented statically at 28℃ for 3 days. After fermentation, mycelia and fermentation broth were collected separately. An equal volume of ethyl acetate was added for ultrasonic extraction. The three extracts were combined and concentrated to dryness under reduced pressure using a rotary evaporator to obtain a crude extract (5.1 g). The crude extract was dissolved in a small amount of methanol and subjected to medium-pressure column chromatography with octadecylsilane-bonded silica gel (ODS). Gradient elution was performed using methanol-water (methanol increased from 10% v / v in increments of 6.5% to 100%), and 14 elution fractions (Fr.1 ~ Fr.14) were collected sequentially. Fr.10 was purified by semi-preparative HPLC using a YMC-Pack ODS-A column (5 μm, 10 × 250 mm) with isocratic elution of 70% CH3OH / H2O (3 mL / min). The retention time was collected (…). t R The chromatographic peak was observed at 15.2 min. After evaporation of the solvent, a yellow oily compound (5.2 mg) was obtained. The obtained compound was analyzed by 1H NMR and 1³C NMR. The spectral data were consistent with the structural data of pestaphilone A (PPA) reported in the literature (Phytochemistry, 2022, 194, 113045.), confirming that the compound was PPA.

[0056] The specific NMR data are as follows: 1 H NMR (500 MHz, MeOD) d H 7.49 (t, J = 1.6 Hz, 1H, H-1), 6.44 (s, 1H, H-4), 5.41 (d, J = 1.2 Hz, 1H, H-5), 5.24 (dt, J = 9.9, 1.6 Hz, 1H, H-12), 4.55(d, J = 2.0 Hz, 1H, H-8), 3.53 (s, 1H. H-10), 2.42 (m, 1H, H-13), 1.73 (d, J =1.5 Hz, 3H, H-17), 1.46 (s, 3H, H-18), 1.42 (m, 1H, H2-14), 1.27 (m, 1H, H2-14), 1.18 (s, 3H, H-19), 0.99 (d, J= 6.6 Hz, 3H, H-16), 0.89 (t, J = 7.4 Hz, 3H, H-15); 13 C NMR (125 MHz, MeOD) d C 201.5 (C-6), 163.0 (C-3), 147.6 (C-4a), 146.5 (C-1), 135.3 (C-12), 128.0 (C-11), 122.9 (C-8a), 106.7 (C-5), 105.9 (C-4), 77.9 (C-7), 73.4 (C-8), 67.9 (C-10), 60.4 (C-9), 35.0 (C-13), 31.4 (C-14), 21.1 (C-16), 19.1 (C-19), 14.2 (C-17), 13.2 (C-18), 12.5 (C-15).

[0057] Example 2 In this example, the PPA obtained in Example 1 was used to verify its therapeutic effect on UIRIx-induced acute kidney injury in mice, as follows.

[0058] Experimental animals: Male C57BL / 6 mice of SPF grade, weighing 22 - 25 g, were provided by the Experimental Animal Center of Southern Medical University (License No.: SCXK(Yue) 2016 - 0041). All mice were housed in an environment with a temperature of 25 ± 1°C and a humidity of 55 ± 5%. The light and dark alternated (12 h light, 12 h dark), and they had free access to water and food. They were housed in the SPF animal room for one week before the experiment to adapt to the environment.

[0059] 1. Experimental method 1.1 Method for constructing the UIRIx animal model The specific steps are as follows: Select mice weighing 22 Male C57BL / 6 mice weighing 25 g were randomly divided into 5 groups of 6 mice each: a sham operation group, a UIRIx model group, and a UIRIx + PPA (2 / 5 / 10 mg / kg) administration group. Mice in the administration groups received intraperitoneal injections of the corresponding doses of PPA solution; mice in the sham and UIRIx model groups received intraperitoneal injections of an equal volume of physiological saline as a blank control. These intraperitoneal injections or blank control treatments were administered for 3 consecutive days. After administration, the mice were anesthetized, and an incision was made along the midline of the abdomen to expose the right renal pedicle, followed by right nephrectomy. The left renal pedicle was then separated and clamped using a non-traumatic microvascular clamp for 30 minutes. The clamp was then released to restore renal perfusion. After confirming normal renal blood flow, the mice were observed for another 5 minutes before the surgical incision was sutured. The UIRIx-induced acute kidney injury mouse model was established 24 hours after renal perfusion was restored.

[0060] 1.2. Observation of kidney tissue histopathological sections The collected organ tissues were fixed in 4.5% formalin, embedded in paraffin, and sectioned. The sections were stained with hematoxylin and eosin, and the tissues were subjected to morphological analysis using an optical microscope.

[0061] 1.3. Serum creatinine and blood urea nitrogen level detection The serum creatinine and urea nitrogen were tested using reagent kits developed in Nanjing, and the specific testing methods were performed entirely in accordance with the instructions.

[0062] 2. Experimental Results UIRIx treatment successfully induced severe acute kidney injury. Pathological morphological observation revealed significant damage characteristics in the kidney tissue: marked swelling of renal tubular epithelial cells, progressing to cell necrosis and shedding; as the injury progressed, eosinophilic protein casts formed within the renal tubular lumen, and significant protein deposition was also observed in the glomeruli. In stark contrast, PPA intervention significantly reduced the severity of kidney injury and effectively improved all the aforementioned pathological abnormalities. Figure 3 The effectiveness of this protective effect can be further confirmed by the significant decrease in two key renal function indicators: serum creatinine (SCr) and blood urea nitrogen (BUN). These two indicators are core biochemical markers reflecting renal filtration function and the degree of damage, and their significant reduction directly demonstrates that PPA has a significant therapeutic effect on UIRIx-induced acute kidney injury. Figure 4 ).

[0063] Example 3 This embodiment investigates the covalently targeted activation of LXRα by PPA and its binding site, as detailed below: Experimental cells: HK-2 cells were used in this invention and cultured in DMEM / F12 medium containing 10% fetal bovine serum and placed in a CO2 incubator (37°C, 5% CO2).

[0064] 1. Experimental Methods 1.1 Modification of PPA probe PPA-P PPA (10 mg, 28.87 μmol, 1 eq) was dissolved in 1 mL of tetrahydrofuran (THF). t-BuOK (6.48 mg, 57.73 μmol, 2 eq) and propargyl bromide (4.67 μL, 43.30 μmol, 1.5 eq) were added sequentially at 15 °C. The mixture was heated and stirred for 12 h. The crude product was purified by preparative HPLC to obtain a yellow solid PPA-P (1.1 mg, yield 9.82%, purity 99.1%).

[0065] 1.2. Immunofluorescence co-localization analysis HK-2 cells were seeded in confocal microplates and treated in two groups: one group was treated with dimethyl sulfoxide (DMSO) and the other with 10 μM PPA for 4 h, followed by treatment with 10 μM PPA-P for 24 h. Subsequently, the cells underwent fixation with 4% paraformaldehyde at room temperature, permeabilization with 0.2% Triton X-100, treatment with premixed Click reagent, blocking with 5% BSA at room temperature, incubation with NR1H3 primary antibody at 4°C, incubation with FITC-labeled secondary antibody at room temperature, and Hoechst staining at room temperature. Finally, images were acquired in the corresponding fluorescence channels using a laser confocal imaging system for subsequent quantitative analysis.

[0066] 1.3. Pull-down assay combined with Western blot analysis of proteins HK-2 cells were incubated for 6 h after being added to PPA-P or an equal volume of DMSO (final concentration 10 μM). After centrifugation, cells were collected and lysed by sonication, retaining the Input group. The remaining cells were treated with 100 μM TBTA, 2 mM NaAsc, 1 mM CuSO4, and 100 μM Iotin-N3, and incubated at room temperature in the dark for 2 h. The cells were then precipitated overnight at -20°C with 10 mL of pre-cooled methanol. The precipitate was reconstituted with 1% SDS by sonication. The supernatant was then used to bind to pretreated streptavidin magnetic beads at room temperature and eluted. Loading buffer was added to the magnetic beads and sonicated. Loading buffer was added to the Input group. Both groups were heated at 95°C for 30 min for denaturation. After centrifugation, the supernatant was used for subsequent analysis.

[0067] 1.4. Identification of Pure Protein Sites LXRα protein was diluted to 1 mg / mL with SEC buffer, and PPA was added to a final concentration of 50 μM. The mixture was incubated at 37°C for 24 h. The mixture was transferred to an activated ultrafiltration membrane centrifuge column, washed with PBS and TEAB buffer, resuspended in TEAB, and incubated overnight at 37°C with shaking. After enzymatic digestion, the filtrate was collected by centrifugation, washed twice with ultrapure water, and the eluents were combined. The eluents were then desalted and eluted using an HLB solid-phase extraction column. The peptides were reconstituted in 0.1% formic acid aqueous solution and analyzed using an LC-MS / MS system.

[0068] 1.5. Purification of protein labels Protein was diluted to 1 mg / mL with PBS, and the molecular probe PPA-P was added to a final concentration of 50 μM. After administration, a premixed click reaction mixture was added and reacted for 2 h. Loading buffer was added directly and the mixture was heated at 95 °C for 10 min. Pure protein samples were separated by 10% SDS-PAGE, and the fluorescence in the gel was visualized by scanning. Coomassie Brilliant Blue staining was performed on the gel to confirm that the loading amount was consistent across groups.

[0069] 1.6. Biolayer Interferometry (BLI) The binding affinity of LXRα-WT and R305A mutant proteins to PPA was determined using a SAS sensor chip in the GatorPrime biofilm interferometry system. The SAS chip was incubated with LXRα-WT or R305A protein solutions for 15 min to immobilize the proteins. A control chip immersed only in buffer was used to correct background. The proteins were then transferred to detection buffer (PBS containing 0.5% DMSO) containing gradient concentrations of PPA (0, 3.125, 6.25, 12.5, 25, 50, 100 μM) to monitor real-time binding signals.

[0070] 2. Experimental Results To clarify the interaction between PPA and LXRα protein, this embodiment conducted a pull-down experiment and simultaneously performed a co-localization experiment of LXRα and PPA / PPA-P in HK-2 cells. The two different experimental methods were used to cross-validate each other, ensuring the reliability of the experimental results. The pull-down experiment results showed that PPA-P successfully precipitated endogenous LXRα protein from HK-2 cells, directly demonstrating the specific binding interaction between the two in cells. Figure 5A). Correspondingly, colocalization experiments showed that in HK-2 cells, PPA-P and LXRα proteins exhibited significant colocalization, mainly overlapping in the same cellular regions. However, when PPA was added for intervention, this colocalization phenomenon was significantly weakened due to the competition between PPA and PPA-P for the binding site of LXRα protein, further confirming the specificity of the binding between PPA and LXRα. Figure 5 B). The above results preliminarily demonstrate that PPA and LXRα protein are covalently bound.

[0071] LXRα consists of 447 amino acids and its structure includes an N-terminal transcription activation domain, a central DNA-binding domain, a flexible hinge region, and a C-terminal ligand-binding domain. To determine the specific binding site of PPA and LXRα, the complex formed by PPA and LXRα was digested with trypsin, and LC-MS / MS analysis was used to identify arginine 305 (Arg305, or R305) in the LXRα ligand-binding domain as the specific site for PPA covalent modification of LXRα. Figure 6 A).

[0072] The probe molecule PPA-P was used to target purified wild-type LXRα (LXRα). ) protein and the R305 site mutant LXRα (LXRα ³ 05 Covalent labeling experiments were performed on the protein, and the results showed that PPA-P can specifically bind to LXRα. Protein, and cannot interact with LXRα ³ 05 Protein binding demonstrates that the R305 site is a necessary site for PPA-P to covalently modify LXRα. Figure 6 B).

[0073] The interaction between LXRα and PPA was verified using BLI technology. The results showed that LXRα The dissociation constant with PPA is 6.06 μM, and the two bind with high affinity in a dose-dependent manner; while LXRα ³ 05 The lack of significant binding interaction with PPA further confirms that the R305 site is the core site for the specific binding of PPA to LXRα. Figure 6 CD).

[0074] Example 4 This embodiment experimentally verified the mechanism of PPA activation of the LXRα-SLC31A1 pathway in combating acute kidney injury, as detailed below.

[0075] 1. Experimental Methods 1.1 Dual-luciferase assay HK-2 cells were seeded in 24-well plates, transfected and drugged according to the protocol provided by Lipofectamine™ 3000. Fluorescence signals were then detected using a dual-luciferase assay kit after adding the appropriate reagents and a microplate reader, with Renin fluorescence as an internal control for calculation of relative activity.

[0076] 1.2. ROS content determination HK-2 cells were seeded in confocal dishes. The control group was cultured normally, the model group was treated with H / R, and the drug-treated group was treated with PPA (10 μM) before H / R. The cells were incubated with the DCFH-DA fluorescent probe (5 μM) at 37°C in the dark for 30 min. The ROS working solution was discarded, the cells were washed three times with PBS, and photographed under an inverted fluorescence microscope.

[0077] 2. Experimental Results Dual-luciferase reporter gene assays confirmed that LXRα significantly induced transcriptional activity of the SLC31A1 gene promoter, and PPA treatment further enhanced this transcriptional activity. Therefore, LXRα can be considered a direct transcriptional regulator of SLC31A1 gene expression. To verify whether the efficacy of PPA in treating acute kidney injury depends on the LXRα–SLC31A1 pathway, targeted validation experiments were conducted. The results showed that in LXRα-silenced HK-2 cells, PPA could not further reduce the levels of related biomarkers induced by H / R deficiency in HK-2 cells. Figure 7 ).

[0078] LXRα can effectively reduce intracellular oxidative stress levels and oxidative damage by regulating SLC31A1 expression, ultimately protecting and repairing mitochondrial function. PPA treatment can further enhance this regulatory process by increasing SLC31A1 expression and reducing intracellular ROS levels, thereby effectively alleviating H / R-induced oxidative stress in HK-2 cells and ensuring normal cellular physiological function. Figure 8 In summary, PPA exerts its therapeutic effect on acute kidney injury by activating the LXRα–SLC31A1 pathway and improving ROS elevation caused by oxidative stress, thus clarifying the core mechanism of action of PPA in treating acute kidney injury.

[0079] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A strain of Aspergillus nidulans, characterized in that, The Aspergillus nidus strain was named Aspergillus nidulans SE44, taxonomically named Aspergillus nidulans It was deposited at the Guangdong Provincial Center for Microbial Culture Collection on April 15, 2026, with accession number GDMCC No: 68088.

2. The method for constructing the Aspergillus nidulans strain according to claim 1, characterized in that, Including pes L gene pes E gene pes F gene pes I gene and pes J gene introduced into chassis cells Aspergillus nidulans The steps in A1145; The pes The nucleotide sequence of the L gene is shown in SEQ ID NO.1; pes The nucleotide sequence of the E gene is shown in SEQ ID NO.2; pes The nucleotide sequence of the F gene is shown in SEQ ID NO.3; pes The nucleotide sequence of gene I is shown in SEQ ID NO.4; pes The nucleotide sequence of the J gene is shown in SEQ ID NO.

5.

3. The construction method according to claim 2, characterized in that, Includes the following steps: (1) Using strains Neopestalotiopsis Using the genomic DNA of sp. SCSIO41422 as a template, PCR amplification was performed to obtain... pes L gene pes E gene pes F gene pes I gene and pes J gene; (2) The gene fragment obtained in step (1) and the linearized vector were co-transformed into competent yeast cells to obtain yeast plasmids; (3) The yeast was transformed into competent E. coli cells, and the presence of the yeast was verified. pes Recombinant plasmids containing the L gene pes E gene and pes Recombinant plasmids containing the F gene pes I gene and pes Recombinant plasmid of the J gene; (4) Transform the recombinant plasmid obtained in step (3) into Aspergillus nidulans and screen for plasmids containing Aspergillus nidulans. pes L gene pes E gene 、 pes F gene pes I gene and pes Aspergillus nidulans of the J gene was used to obtain strains. Aspergillus nidulans SE44.

4. The construction method according to claim 3, characterized in that, In step (2), the linearized vector is a vector obtained by double digestion and linearization of pYTU plasmid, pYTR plasmid, and pYTP plasmid with restriction endonucleases PacI and SwaI. Preferably, in step (3), the competent Escherichia coli cells are Escherichia coli DH5α competent cells.

5. A method for preparing pseudophenanthrene compounds, characterized in that, The pseudophenanthrone compound is pseudophenanthrone A, with the structure shown in formula (1); the pseudophenanthrone compound is isolated from the fermentation product of the Aspergillus nidulans strain according to claim 1; Equation (1).

6. The preparation method according to claim 5, characterized in that, Includes the following steps: (1) For the Aspergillus nidus strain Aspergillus nidulans SE44 undergoes fermentation treatment; (2) The fermentation product was extracted with ethyl acetate and concentrated to obtain a crude extract; (3) The pseudophenanthrene compounds were obtained by gradient elution and purification by reverse silica gel column chromatography.

7. The preparation method according to claim 6, characterized in that, In step (1), the fermentation treatment is as follows: the Aspergillus nidulans strain is fermented. Aspergillus nidulans SE44 was inoculated into liquid CD-ST medium and allowed to ferment statically; Preferably, each liter of the liquid CD-ST culture medium contains: 20 g of soluble starch, 20 g of vitamin-free casein hydrolysate, 50 mL of nitrate solution, 1 mL of trace element solution, and the remainder is water; the nitrate solution contains: 120 g / L sodium nitrate, 10.4 g / L potassium chloride, 10.4 g / L magnesium sulfate, and 30.4 g / L potassium dihydrogen phosphate; the trace element solution contains: 22 g / L zinc sulfate heptahydrate, 11 g / L boric acid, 5 g / L manganese chloride tetrahydrate, 1.6 g / L ferrous sulfate heptahydrate, 1.6 g / L cobalt chloride hexahydrate, 1.6 g / L copper sulfate pentahydrate, 1.1 g / L ammonium heptamolybdate tetrahydrate, and 50 g / L EDTA; the pH of the trace element solution is adjusted to 6.5 with KOH.

8. The preparation method according to claim 5, characterized in that, In step (3), the reverse silica gel column chromatography gradient elution yields fractions 1-14; the eluent for the reverse silica gel column chromatography gradient elution is methanol-water; the gradient for the reverse silica gel column chromatography gradient elution is methanol / water = 10% / 90% → 16.5% / 83.5% → 23% / 77% → 29.5% / 70.5% → 36% / 64% → 42.5% / 57.5% → 49% / 51% → 55.5% / 44.5% → 62% / 38% → 68.5% / 31.5% → 75% / 25% → 81.5% / 18.5% → 88% / 12% → 94.5% / 5.5% → 100% / 0. Preferably, fraction 10 obtained by reverse silica gel column chromatography gradient elution is purified to obtain pseudophenanthrene compounds; the purification is a semi-preparative HPLC purification; the mobile phase of the semi-preparative HPLC purification is 70% CH3OH / H2O, the flow rate is 3 mL / min, and the retention time is t. R =15.2 min.

9. The application of phenanthrene compounds in the preparation of LXRα agonists, characterized in that, The pseudophenanthrone compound is pseudophenanthrone A, with the structure shown in formula (1). Equation (1).

10. The use of phenanthrene compounds and their drug salts in the preparation of medicaments for the treatment and / or prevention of liver and kidney diseases, characterized in that, The pseudophenanthrone compound is pseudophenanthrone A, with the structure shown in formula (1). Equation (1) Preferably, the liver and kidney disease is a liver and kidney disease caused by lipid metabolism and oxidative stress disorders; Preferably, the liver and kidney diseases include non-alcoholic fatty liver disease, diabetic nephropathy, and acute kidney injury.